Rune Labs Taps Tempus Exec as New CEO to Expand AI-Enabled Neurology Care

Core Insights - Rune Labs has appointed Amy Gordon Franzen as the new Chief Executive Officer to lead the company's growth, particularly in expanding its AI platform StrivePD for neurological conditions beyond Parkinson's Disease [1][4] - The company aims to enhance its partnerships with clinicians, payers, and biopharma leaders to improve patient care and expand its commercial reach [3][5] Company Overview - Rune Labs specializes in precision medicine for neurology, utilizing advanced AI and FDA-cleared algorithms to support care delivery and therapy development [5] - The StrivePD platform, launched in 2022, has evolved into a comprehensive software ecosystem that facilitates remote care, AI-enabled symptom tracking, and real-world evidence generation for Parkinson's patients [3][5] Leadership Background - Amy Franzen previously held significant roles at Tempus, Groupon, Nike, and McKinsey & Company, where she focused on building partnerships and scaling clinical trial organizations [2] - Co-founder Brian Pepin will transition to President, Biopharma and Platform, to lead the expansion of Rune Labs' biopharma partnerships and research portfolio [1][3] Strategic Goals - The company plans to extend its AI-enabled care infrastructure to address a broader range of neurological conditions, including Alzheimer's disease and other forms of dementia [1][3] - Franzen emphasized the importance of scaling the commercial and clinical infrastructure to integrate more deeply with trial sponsors, payers, and health systems [5]